Case of mastocytemia and systemic mastocytosis in a dog: ProCyte Dx and Sysmex XT-2000i scattergram findings, morphologic features, and c-kit somatic mutation analysis.
KIT tyrosine kinase receptor
MCT
PCR
blood smear
dot plot
exon 9
extracutaneous/extramucosal
liver and spleen cytology
Journal
Veterinary clinical pathology
ISSN: 1939-165X
Titre abrégé: Vet Clin Pathol
Pays: United States
ID NLM: 9880575
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
20
07
2022
received:
29
04
2022
accepted:
01
08
2022
medline:
6
6
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
A 10-year-old female Golden Retriever was presented for a recheck after the complete removal of low-grade complex mammary carcinoma. The in-house ProCyte Dx automated counts revealed moderate regenerative anemia and moderate eosinophilia. The ProCyte Dx WBC scattergram showed a cloud in an unusual place parallel and to the right of the monocyte dot plot location. Cells were classified as either monocytes or neutrophils with no clear separation. Complete blood count analysis performed in the laboratory on a Sysmex XT-2000iV analyzer showed moderate regenerative anemia and WBC count within RI; a differential count was not provided by the instrument. On the Sysmex XT-2000iV DIFF scattergram, neutrophil and eosinophil dot plots were present at the respective locations and appeared separated, but the instrument did not provide numerical results. In addition to the normal lymphocyte dot plot location, the second cloud of cells classified as lymphocytes was displayed to the right of the monocyte dot plot area. On the WBC/BASO scattergram, the second population of cells was present above and to the right of the leukocyte cluster. Morphologic assessment of the blood smear detected mastocytemia with 16% poorly granulated and degranulated mast cells. FNAs from the liver and spleen contained large aggregates of poorly granulated mast cells. C-kit somatic mutation screening detected the presence of point mutation S479I in exon 9 of the canine c-KIT gene. This is the first description of abnormal scattergrams from ProCyte Dx and Sysmex XT-2000iV analyzers in a dog with concurrent mastocytemia and systemic mastocytosis, and where cytologic assessments of a blood smear, liver, and spleen, and c-kit somatic mutation analysis were performed.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-340Informations de copyright
© 2023 American Society for Veterinary Clinical Pathology.
Références
Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 2006;8:104-111.
Letard S, Yang Y, Hanssens K, et al. Gain-of function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6:1137-1145.
Gentilini F, Mantovani V, Turba ME. The use of COLD-PCR, DHPLC and GeneScanning for the highly sensitive detection of c-KIT somatic mutations in canine mast cell tumours. Vet Comp Oncol. 2015;13:218-228.
Stockham SL, Basel DL, Schmidt DA. Mastocytemia in dogs with acute inflammatory diseases. Vet Clin Pathol. 1986;15:16-21.
McManus PM. Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). J Am Vet Med Assoc. 1999;215:355-357.
Cayatte SM, McManus PM, Miller WH Jr, Scott DW. Identification of mast cells in buffy coat preparations from dogs with inflammatory skin diseases. J Am Vet Med Assoc. 1995;206:325-326.
Stockham SL, Scott MA. Fundamentals of veterinary clinical pathology. 2nd ed. Wiley-Blackwell; 2008:88-89.
Fujino Y, Nakamura Y, Matsumoto H, et al. Development and evaluation of a novel in-clinic automated hematology analyzer, ProCyte dx, for canine erythrocyte indices, leukogram, platelet counts and reticulocyte counts. J Vet Med Sci. 2013;75:1519-1524.
Conrado FO, Raskin RE. What is your diagnosis? Purple granules within neutrophils of a dog. Vet Clin Pathol. 2017;46:639-640.
Sulce M, Marconato L, Martano M, et al. Utility of flow cytometry in canine primary cutaneous and matched nodal mast cell tumor. Vet J. 2018;242:15-23.
Willmann M, Yuzbasiyan-Gurkan V, Marconato L, et al. Proposed diagnostic criteria and classification of canine mast cell neoplasms: a consensus proposal. Front Vet Sci. 2021;8:755258.
Takahashi T, Kadosawa T, Nagase M, et al. Visceral mast cell tumors in dogs: 10 cases (1982-1997). J Am Vet Med Assoc. 2000;216(2):222-226.
Aceino A, Jeffery U, Piccione J, Hodo CL. Systemic mastocytosis with subcutaneous hemorrhage and edema in a greyhound dog: case report and review of diagnostic criteria. J Vet Diagn Invest. 2021;33:95-100.
O'Keefe DA, Couto CG, Burke-Schwartz C, Jacobs RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med. 1987;1:75-80.
Beltran E, de Stefani A, Stewart J, De Risio L, Johnson V. Disseminated mast cell tumor infiltrating the sphenoid bone and causing blindness in a dog. Vet Ophthalmol. 2010;13:184-189.
Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261-1270.
Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420-1427.
Nakano Y, Kobayashi M, Bonkobara M, Takanosu M. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor. Vet Immunol Immunopathol. 2017;188:84-88.
Thamm DH, Avery AC, Berlato D, et al. Prognostic and predictive significance of KIT protein expression and c-KIT gene mutation in canine cutaneous mast cell tumours: a consensus of the oncology-pathology working group. Vet Comp Oncol. 2019;17:451-455.
London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9:2755-2768.
Weishaar KM, Ehrhart EJ, Avery AC, et al. c-kit mutation and localization status as response predictors in mast cell tumors in dogs treated with prednisone and toceranib or vinblastine. J Vet Intern Med. 2018;32:394-405.
Horta RDS, Giuliano A, Lavalle GE, et al. Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. Oncol Lett. 2018;15:129-136.
de Nardi AB, Dos Santos HR, Fonseca-Alves CE, et al. Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell tumors. Cell. 2022;11:618.
Thompson JJ, Yager JA, Best SJ, et al. Canine subcutaneous mast cell tumors. Vet Pathol. 2010;48:169-181.
Thompson JJ, Morrison JA, Pearl DL, et al. Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors. Vet Pathol. 2015;53:545-558.
Moirano SJ, Lima SF, Hume KR, Brodsky EM. Association of prognostic features and treatment on survival time of dogs with systemic mastocytosis: a retrospective analysis of 40 dogs. Vet Comp Oncol. 2018;16:E194-E201.
Blackwood L, Murphy S, Buracco P, et al. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012;10:e1-e29.